Cipla’s New York plant gets FDA no-action classification
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.

Filing board Industry desk
30 open filings
FDA gave Cipla’s InvaGen plant in Hauppauge a No Action Indicated classification after its October 2026 inspection, easing regulatory uncertainty without approving any drug or product.


FDA’s MAPP 5100.7 took effect on 10 November. The internal guideline covers multidisciplinary NDA and BLA reviews, fina…

FDA cleared tubeless insulin systems from Tandem and MiniMed, Medtronic agreed to buy Contego Medical for $380M, and CD…

FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B. Also: Teva settles price-fix…

Marrow Therapeutics has raised $173 million for transferrin-receptor drug delivery into bone marrow. Its MAR-101 progra…

Flagship Pioneering commits £100M to a London origination lab for AI-native platform companies, expecting £500M more in…

KONEX-listed Ensol Bio Science will pursue a first-half 2026 KOSDAQ transfer listing, anchored by FDA accelerated-appro…

Regulation & FDA

Regulation & FDA

Regulation & FDA

Regulation & FDA

Regulation & FDA

Regulation & FDA

Regulation & FDA

Regulation & FDA

Deals & Business